Hba1C Testing Market: Market Size & Forecast 2026

HbA1c testing measures the percentage of hemoglobin coated with glucose over roughly two to three months, serving as the clinical gold standard for diabetes diagnosis and long-term glycemic management. The market encompasses instruments, reagents, test kits, and consumables used in clinical laboratories, hospitals, physician offices, and point-of-care environments. At $2.21 billion in 2025, the sector sits within the broader in-vitro diagnostics industry and continues to benefit from sustained demand across both developed and emerging healthcare systems.

• •Measures average blood glucose over 2-3 months, critical for diabetes diagnosis and monitoring
• •Includes laboratory-based analyzers, immunoassay systems, and point-of-care devices
• •Marked by steady double-digit growth potential through 2030

The primary catalyst is the escalating global prevalence of diabetes and prediabetes, driven by sedentary lifestyles, obesity, and aging populations. Greater awareness of early screening and routine monitoring, supported by public health initiatives and clinical guidelines, has expanded test volumes in both institutional and non-institutional settings. Additionally, the shift toward decentralized care and point-of-care solutions enables faster clinical decisions, further boosting adoption.

• •Rising global diabetes incidence and aging demographics increase screening volumes
• •Growing emphasis on preventive care and routine monitoring in primary care settings
• •Point-of-care testing adoption delivers rapid results, supporting treatment adjustments

The market splits into instruments, reagents/kits, and consumables, with laboratory-based testing holding the largest share while point-of-care grows faster. Geographically, North America leads due to high diabetes prevalence, advanced healthcare infrastructure, and favorable reimbursement frameworks. Asia-Pacific is the fastest-expanding region, propelled by improving access to care, rising disease burden, and investments in diagnostic capacity.

• •North America holds the dominant share, supported by high disease burden and strong reimbursement
• •Asia-Pacific registers the highest growth rate, driven by expanding healthcare access and rising diabetes rates
• •Laboratory segment leads in revenue; point-of-care segment outpaces in growth velocity

What are the recent trends and outlook?

Integration of HbA1c testing with broader metabolic panels and connectivity to electronic health records reflects an industry shift toward comprehensive diabetes management platforms. Home testing kits and patient self-monitoring devices are gaining ground, aligned with consumer demand for convenient chronic disease management. Over the forecast horizon, the market is expected to sustain an approximate 8.7% annual growth, underpinned by continuous product innovation and expanding global screening programs.

• •Connectivity and integration with digital health platforms are shaping next-generation testing solutions
• •Home-based and self-testing products are emerging as a notable niche segment
• •Market projected to maintain robust growth through 2030, supported by innovation and expanded screening initiatives